{"id":"benefix","rwe":[],"tags":[],"trials":[],"_chembl":null,"aliases":["Recombinant factor IX (rFIX)","recombinant coagulation factor IX"],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Benefix","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:18:04.016987+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:18:09.600941+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Benefix","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:18:09.798869+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Coagulation factor IX exogenous protein","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:18:10.816491+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2109205/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:18:10.485739+00:00"}},"offLabel":[],"timeline":[],"_dailymed":{"setId":"85faa5bc-cee5-4ef1-8d80-bdbcb7eba1e4","title":"BENEFIX (COAGULATION FACTOR IX (RECOMBINANT)) KIT [WYETH BIOPHARMA DIVISION OF WYETH PHARMACEUTICALS LLC]"},"ecosystem":[],"_scrapedAt":"2026-03-28T00:20:42.713Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:18:12.122108+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT03569891","phase":"PHASE3","title":"HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2018-06-27","conditions":"Hemophilia B","enrollment":67},{"nctId":"NCT06379789","phase":"PHASE1, PHASE2","title":"A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-09-11","conditions":"Hemophilia B","enrollment":130},{"nctId":"NCT01687608","phase":"PHASE1, PHASE2","title":"Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baxalta now part of Shire","startDate":"2013-02-11","conditions":"Hemophilia B","enrollment":30},{"nctId":"NCT05568459","phase":"","title":"A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-01-17","conditions":"Hemophilia B","enrollment":11},{"nctId":"NCT03307980","phase":"PHASE2","title":"Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2017-06-22","conditions":"Hemophilia B","enrollment":21},{"nctId":"NCT06003387","phase":"PHASE3","title":"Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)","status":"RECRUITING","sponsor":"CSL Behring","startDate":"2024-01-30","conditions":"Hemophilia B","enrollment":35},{"nctId":"NCT07094087","phase":"PHASE3","title":"Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)","status":"RECRUITING","sponsor":"CSL Behring","startDate":"2025-09-15","conditions":"Complex Cardiovascular Surgery With Cardiopulmonary Bypass","enrollment":200},{"nctId":"NCT03861273","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2019-07-29","conditions":"Hemophilia B","enrollment":51},{"nctId":"NCT06349473","phase":"PHASE1","title":"A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)","status":"RECRUITING","sponsor":"Equilibra Bioscience LLC","startDate":"2024-05-10","conditions":"Healthy Participants, Hemophilia A, Hemophilia B","enrollment":31},{"nctId":"NCT04590950","phase":"","title":"Dosage and PD Study of Eftrenonacog-alfa","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-12-18","conditions":"Severe Haemophilia B","enrollment":15},{"nctId":"NCT05568719","phase":"PHASE3","title":"Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively","status":"RECRUITING","sponsor":"Pfizer","startDate":"2022-12-28","conditions":"Hemophilia A, Hemophilia B","enrollment":173},{"nctId":"NCT07425327","phase":"","title":"Validity and Reliability of the Two-minute Step Test in Hemophilia","status":"NOT_YET_RECRUITING","sponsor":"Hasan Kalyoncu University","startDate":"2026-02-25","conditions":"Hemophilia, Step, Reliability and Validity","enrollment":35},{"nctId":"NCT06008938","phase":"","title":"An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B","status":"RECRUITING","sponsor":"CSL Behring","startDate":"2023-06-15","conditions":"Hemophilia B","enrollment":500},{"nctId":"NCT05932914","phase":"","title":"Liver Biopsy Following Gene Therapy For Hemophilia","status":"NOT_YET_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2026-03","conditions":"Hemophilia A, Hemophilia B","enrollment":8},{"nctId":"NCT05145127","phase":"PHASE3","title":"Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors","status":"RECRUITING","sponsor":"Pfizer","startDate":"2021-11-17","conditions":"Hemophilia A, Hemophilia B","enrollment":245},{"nctId":"NCT07080905","phase":"PHASE3","title":"Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B","status":"RECRUITING","sponsor":"CSL Behring","startDate":"2025-07-28","conditions":"Hemophilia B","enrollment":20},{"nctId":"NCT05662319","phase":"PHASE3","title":"A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2023-02-01","conditions":"Hemophilia","enrollment":91},{"nctId":"NCT00979238","phase":"PHASE1","title":"Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector For Gene Transfer in Hemophilia B","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2010-02-22","conditions":"Hemophilia B","enrollment":14},{"nctId":"NCT06929260","phase":"PHASE1","title":"A Study to Evaluate the Effect of Ceralasertib on Drug X, Drug Y and Drug Z","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2025-05-21","conditions":"Advanced Solid Tumours","enrollment":1},{"nctId":"NCT04647227","phase":"PHASE4","title":"SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors","status":"RECRUITING","sponsor":"American Thrombosis and Hemostasis Network","startDate":"2021-06-28","conditions":"Hemophilia A With Inhibitor, Hemophilia B With Inhibitor","enrollment":55},{"nctId":"NCT06399289","phase":"PHASE3","title":"Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese Subjects With Hemophilia B Previously Treated With FIX Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"CSL Behring","startDate":"2024-07-28","conditions":"Hemophilia B","enrollment":23},{"nctId":"NCT05568888","phase":"PHASE3","title":"Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study )","status":"TERMINATED","sponsor":"CSL Behring","startDate":"2023-03-28","conditions":"Traumatic Injury","enrollment":1366},{"nctId":"NCT06700096","phase":"PHASE3","title":"An Open-Label, Comparative Study of the Efficacy, Safety and Pharmacodynamics of Single Dose of ANB-002 in Patients With Hemophilia B","status":"RECRUITING","sponsor":"Biocad","startDate":"2024-11-07","conditions":"Hemophilia B","enrollment":24},{"nctId":"NCT05044845","phase":"","title":"Needs Assessment of Knowledge, Beliefs, and Attitudes of Patients With Hemophilia B About Gene Therapy","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-01-18","conditions":"Gene Therapy, Hemophilia B","enrollment":150},{"nctId":"NCT03587116","phase":"PHASE3","title":"A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-07-26","conditions":"Hemophilia B, Hemophilia A","enrollment":212},{"nctId":"NCT04244981","phase":"PHASE4","title":"Efficacy of Prothrombin Complex Concentrate Reducing Perioperative Blood Loss in Cardiac Surgery","status":"RECRUITING","sponsor":"SHI Jia","startDate":"2023-10-25","conditions":"Cardiac Surgical Procedures","enrollment":820},{"nctId":"NCT06611436","phase":"PHASE1, PHASE2","title":"BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B","status":"RECRUITING","sponsor":"Be Biopharma","startDate":"2024-12-04","conditions":"Hemophilia B, Hemophilia B, Moderately Severe or Severe","enrollment":24},{"nctId":"NCT03901755","phase":"","title":"An International Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2019-09-12","conditions":"Hemophilia B","enrollment":151},{"nctId":"NCT04023019","phase":"","title":"Treatment of Hemophilia A Patients With FVIII Inhibitors","status":"RECRUITING","sponsor":"Emory University","startDate":"2020-03-17","conditions":"Hemophilia A","enrollment":120},{"nctId":"NCT06634836","phase":"","title":"Patient Interview Study to Explore the Impact of Gene Therapy in Hemophilia A & B","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2025-03-17","conditions":"Hemophilia A, Hemophilia B","enrollment":""},{"nctId":"NCT05360706","phase":"","title":"Study of AAV5-hFIX in Severe or Moderately Severe Haemophilia B","status":"ACTIVE_NOT_RECRUITING","sponsor":"CSL Behring","startDate":"2021-03-18","conditions":"Hemophilia B","enrollment":9},{"nctId":"NCT04543383","phase":"PHASE1","title":"A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-07-27","conditions":"Healthy","enrollment":52},{"nctId":"NCT05611801","phase":"PHASE3","title":"A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B","status":"RECRUITING","sponsor":"Pfizer","startDate":"2022-12-09","conditions":"Hemophilia A, Hemophilia B","enrollment":100},{"nctId":"NCT07101224","phase":"","title":"Data Registry in Chinese Hemophilia A and B Patients","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2017-05-07","conditions":"Hemophilia A, Hemophilia B","enrollment":200},{"nctId":"NCT06144112","phase":"PHASE4","title":"Fibrinogen Concentrates Versus Cryoprecipitate in Liver Transplant Surgery","status":"NOT_YET_RECRUITING","sponsor":"Konkuk University Medical Center","startDate":"2025-09-01","conditions":"Liver Diseases","enrollment":92},{"nctId":"NCT05962398","phase":"","title":"Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)","status":"ENROLLING_BY_INVITATION","sponsor":"CSL Behring","startDate":"2023-08-30","conditions":"Hemophilia B","enrollment":56},{"nctId":"NCT01154231","phase":"","title":"BeneFIX Drug Use Results Survey [All-Case Surveillance]","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-10-29","conditions":"Hemophilia B","enrollment":314},{"nctId":"NCT02740413","phase":"","title":"Treatment Patterns And Outcomes In Patients Treated With Benefix Or Refacto/Refacto AF - A Swedish Cohort Study","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-01-11","conditions":"Hemophilia A, Hemophilia B","enrollment":86},{"nctId":"NCT05203679","phase":"PHASE2, PHASE3","title":"Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Xinzhi BioMed Co., Ltd.","startDate":"2021-12-30","conditions":"Hemophilia B","enrollment":32},{"nctId":"NCT06120582","phase":"PHASE1, PHASE2","title":"Study of the Safety, Pharmacodynamics and Efficacy of ANB-002 in Patients With Hemophilia B (SAFRAN)","status":"RECRUITING","sponsor":"Biocad","startDate":"2023-05-02","conditions":"Hemophilia B","enrollment":28},{"nctId":"NCT03938792","phase":"PHASE3","title":"Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-03-09","conditions":"Hemophilia A, Hemophilia B","enrollment":189},{"nctId":"NCT05437211","phase":"NA","title":"A Proof-of-concept Study to Reduce Treatment Burden in Haemophilia Participants Receiving Factor VIII and Factor IX Infusions","status":"COMPLETED","sponsor":"Takeda","startDate":"2023-06-23","conditions":"Hemophilia","enrollment":24},{"nctId":"NCT03341156","phase":"PHASE3","title":"Administration of Prothrombin Complex Concentrate vs. Standard Transfusion During/After Heart Transplantation","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2018-07-11","conditions":"Heart Disease End Stage, Heart Failure，Congestive","enrollment":14},{"nctId":"NCT05789537","phase":"PHASE2","title":"A Study of SerpinPC in Participants with Hemophilia B (HemB) with Inhibitors","status":"TERMINATED","sponsor":"ApcinteX Ltd","startDate":"2023-07-28","conditions":"Hemophilia B with Inhibitor, Hemophilia B","enrollment":3},{"nctId":"NCT05789524","phase":"PHASE2","title":"The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B","status":"TERMINATED","sponsor":"ApcinteX Ltd","startDate":"2023-07-06","conditions":"Hemophilia a, Hemophilia B","enrollment":60},{"nctId":"NCT05630651","phase":"NA","title":"The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients.","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-04-19","conditions":"Hemophilia B","enrollment":6},{"nctId":"NCT05641610","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Efficacy of ZS801 in Adult Hemophilia B Patients","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-02-16","conditions":"Hemophilia B","enrollment":21},{"nctId":"NCT05709288","phase":"PHASE1","title":"Gene Therapy for Hemophilia B Patients Aged 12-18 Years Old","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-03-23","conditions":"Hemophilia B","enrollment":9},{"nctId":"NCT05152732","phase":"EARLY_PHASE1","title":"Safety and Tolerability of VGB-R04 in Patients With Haemophilia B","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2021-12-28","conditions":"Hemophilia B","enrollment":3},{"nctId":"NCT04135300","phase":"NA","title":"Gene Therapy for Chinese Hemophilia B","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2019-10-16","conditions":"Hemophilia B","enrollment":10},{"nctId":"NCT05281718","phase":"EARLY_PHASE1","title":"Factor IX as Adjunctive Therapy to Emicizumab (EMIX)","status":"COMPLETED","sponsor":"Tulane University","startDate":"2022-08-01","conditions":"Hemophilia A","enrollment":12},{"nctId":"NCT05667805","phase":"PHASE4","title":"Coagulation in Cirrhosis","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2023-01-19","conditions":"Liver Cirrhosis","enrollment":400},{"nctId":"NCT06747416","phase":"PHASE2","title":"KN057 Multiple Dose Study in Patients with Hemophilia a or Hemophilia B with or Without Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Alphamab Co., Ltd.","startDate":"2025-09-02","conditions":"Hemophilia a and B","enrollment":24},{"nctId":"NCT05010707","phase":"PHASE2","title":"Transgender Estradiol Affirming Therapy","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2021-08-02","conditions":"Transgenderism","enrollment":39},{"nctId":"NCT06627218","phase":"NA","title":"Liberal or Adhere to Recommendations for PCC Management in Major Bleeding Following Trauma","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-01-01","conditions":"Traumatic Bleeding","enrollment":650},{"nctId":"NCT03055611","phase":"","title":"A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2017-05-09","conditions":"Haemophilia A, Haemophilia B","enrollment":201},{"nctId":"NCT03655340","phase":"","title":"A Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in France","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2018-09-12","conditions":"Haemophilia B","enrollment":91},{"nctId":"NCT02937831","phase":"","title":"RIXUBIS Drug Use-Result Survey (Japan)","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2016-11-16","conditions":"Hemophilia B","enrollment":6},{"nctId":"NCT02695160","phase":"PHASE1","title":"Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B","status":"TERMINATED","sponsor":"Sangamo Therapeutics","startDate":"2016-11-15","conditions":"Hemophilia B","enrollment":1},{"nctId":"NCT03489291","phase":"PHASE2","title":"Dose Confirmation Trial of AAV5-hFIXco-Padua","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2018-07-24","conditions":"Hemophilia B","enrollment":3},{"nctId":"NCT02777424","phase":"PHASE4","title":"CPP Versus PFC to Correct Coagulation Disorders in Adult Neurosurgical Patients","status":"COMPLETED","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2016-01-21","conditions":"Intracranial Hemorrhages","enrollment":18},{"nctId":"NCT03855280","phase":"PHASE3","title":"Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B","status":"COMPLETED","sponsor":"Medexus Pharma, Inc.","startDate":"2020-01-16","conditions":"Hemophilia B","enrollment":21},{"nctId":"NCT04628871","phase":"","title":"Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sangamo Therapeutics","startDate":"2020-11-03","conditions":"Hemophilia B, Mucopolysaccharidosis I, Mucopolysaccharidosis II","enrollment":13},{"nctId":"NCT05127681","phase":"NA","title":"Bone Microarchitecture in Men With Hemophilia","status":"TERMINATED","sponsor":"Hospices Civils de Lyon","startDate":"2023-08-01","conditions":"Severe Hemophilia A, Osteoporosis","enrollment":10},{"nctId":"NCT03921294","phase":"PHASE4","title":"HemLibra Prophylaxis in Patients With Hemophilic Pseudotumor","status":"TERMINATED","sponsor":"Indiana Hemophilia &Thrombosis Center, Inc.","startDate":"2019-05-15","conditions":"Haemophilic Pseudotumour","enrollment":1},{"nctId":"NCT04567511","phase":"PHASE4","title":"Hemlibra in Mild Hemophilia A","status":"RECRUITING","sponsor":"Indiana Hemophilia &Thrombosis Center, Inc.","startDate":"2022-07-25","conditions":"Factor VIII Deficiency, Congenital","enrollment":20},{"nctId":"NCT06144099","phase":"PHASE4","title":"Prothrombin Complex Concentrate vs Fresh Frozen Plasma in Goal-directed Bleeding Management in Non-cardiac Surgery","status":"UNKNOWN","sponsor":"Konkuk University Medical Center","startDate":"2024-03-01","conditions":"Prostate Cancer, Spine, Open, Hip Osteoarthritis","enrollment":154},{"nctId":"NCT01561391","phase":"PHASE4","title":"Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"1998-04","conditions":"Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors","enrollment":36},{"nctId":"NCT04019015","phase":"PHASE2","title":"Prehospital Kcentra for Hemorrhagic Shock","status":"UNKNOWN","sponsor":"Oregon Health and Science University","startDate":"2021-03-15","conditions":"Trauma Injury","enrollment":166},{"nctId":"NCT05548777","phase":"","title":"Andexanet Alfa and 4F-PCC Use in Patients Hospitalised With an Anticoagulant-related Major Bleed","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-09-15","conditions":"Anticoagulant-related Major Bleed","enrollment":5480},{"nctId":"NCT06144125","phase":"PHASE4","title":"Prothrombin Complex Concentrate vs Fresh Frozen Plasma in Goal-directed Bleeding Management in Cardiac Surgery","status":"UNKNOWN","sponsor":"Konkuk University Medical Center","startDate":"2024-03-01","conditions":"Cardiac Valve Disease","enrollment":152},{"nctId":"NCT06125756","phase":"EARLY_PHASE1","title":"Safety and Efficacy Clinical Study of Severe Hemophilia B Treatment With KL001","status":"UNKNOWN","sponsor":"Affiliated Hospital of Guangdong Medical University","startDate":"2023-12-20","conditions":"Hemophilia B Without Inhibitor","enrollment":9},{"nctId":"NCT06119659","phase":"EARLY_PHASE1","title":"Safety and Efficacy Clinical Study of Severe Hemophilia B Treatment With KL001","status":"UNKNOWN","sponsor":"Zhejiang University","startDate":"2023-11-20","conditions":"Hemophilia B Without Inhibitor","enrollment":9},{"nctId":"NCT05217992","phase":"","title":"Are There Differences Between Carriers of Haemophilia A and B?","status":"COMPLETED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2021-05-25","conditions":"Hemophilia","enrollment":900},{"nctId":"NCT02803502","phase":"NA","title":"Does the Thrombin Generation Test Performed During the Pharmacokinetic Profile of the Substitutive Factor VIII Bring Benefits to the Personalized Treatment of Pediatric Patients and Adult Hemophilia A Patients Under Prophylaxis ?","status":"UNKNOWN","sponsor":"Brugmann University Hospital","startDate":"2017-01","conditions":"Hemophilia","enrollment":50},{"nctId":"NCT05164471","phase":"PHASE1, PHASE2","title":"Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia B","status":"TERMINATED","sponsor":"Spur Therapeutics","startDate":"2021-12-06","conditions":"Hemophilia B","enrollment":6},{"nctId":"NCT03641703","phase":"PHASE1, PHASE2","title":"A Long-Term Follow-Up Study of Haemophilia B Patients Who Have Undergone Gene Therapy","status":"TERMINATED","sponsor":"Spur Therapeutics","startDate":"2018-07-10","conditions":"Hemophilia B","enrollment":10},{"nctId":"NCT05889754","phase":"","title":"Reliability and Validity of the Turkish Version of the PedHAL","status":"UNKNOWN","sponsor":"Hasan Kalyoncu University","startDate":"2023-05-30","conditions":"Hemophilia, Hemophilia A, Severe, Hemophilia B","enrollment":50},{"nctId":"NCT03075670","phase":"PHASE1","title":"A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-03-07","conditions":"Congenital Bleeding Disorder, Haemophilia B","enrollment":15},{"nctId":"NCT04055051","phase":"","title":"ATHN 11: Liver Transplantation Outcomes Study","status":"COMPLETED","sponsor":"American Thrombosis and Hemostasis Network","startDate":"2020-06-18","conditions":"Hemophilia A and B, Liver Transplantation","enrollment":86},{"nctId":"NCT05804734","phase":"","title":"Vitamin K Antagonist Versus Direct Oral Anticoagulant Treatments in Hemophilia","status":"COMPLETED","sponsor":"Groupe Maladies hémorragiques de Bretagne","startDate":"2021-06-01","conditions":"Hemophilia A, Hemophilia B, Anticoagulant-induced Bleeding","enrollment":54},{"nctId":"NCT03533504","phase":"","title":"Web Accessible Population Pharmacokinetics Service - Hemophilia: Sources of Variability","status":"UNKNOWN","sponsor":"McMaster University","startDate":"2018-05-09","conditions":"Hemophilia A, Hemophilia B","enrollment":1000},{"nctId":"NCT02740335","phase":"PHASE3","title":"Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.","status":"COMPLETED","sponsor":"Octapharma","startDate":"2017-06-08","conditions":"Significant Bleeding Risk","enrollment":208},{"nctId":"NCT03045068","phase":"PHASE4","title":"Platelet Transfusion During Neonatal Open Heart Surgery","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2017-04-11","conditions":"Cardiac Disease, Cardiac Surgery, Cardiopulmonary Bypass","enrollment":46},{"nctId":"NCT03549871","phase":"PHASE3","title":"A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2018-07-25","conditions":"Hemophilia","enrollment":80},{"nctId":"NCT03809481","phase":"PHASE3","title":"Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban","status":"TERMINATED","sponsor":"Aspen Global Incorporated","startDate":"2019-05-16","conditions":"Heparin-induced Thrombocytopenia","enrollment":7},{"nctId":"NCT03369444","phase":"PHASE1, PHASE2","title":"A Factor IX Gene Therapy Study (FIX-GT)","status":"TERMINATED","sponsor":"University College, London","startDate":"2017-12-05","conditions":"Hemophilia B","enrollment":10},{"nctId":"NCT03218722","phase":"PHASE3","title":"Early Administration of Prothrombin Concentrate Complex in Patients With Acute Hemorrhage Following Severe Trauma","status":"COMPLETED","sponsor":"University Hospital, Grenoble","startDate":"2017-12-29","conditions":"Shock, Hemorrhagic","enrollment":350},{"nctId":"NCT03565237","phase":"PHASE4","title":"RIXUBIS PMS India (RIXUBIS PMS)","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2018-12-07","conditions":"Hemophilia B","enrollment":25},{"nctId":"NCT02053792","phase":"PHASE3","title":"A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2014-02-06","conditions":"Hemophilia B","enrollment":97},{"nctId":"NCT05442528","phase":"","title":"Lead-in Study of VGB-R04 Gene Therapy for Hemophilia B-- An Observational Survey Analysis Study","status":"UNKNOWN","sponsor":"Shanghai Vitalgen BioPharma Co., Ltd.","startDate":"2022-08","conditions":"Hemophilia B","enrollment":20},{"nctId":"NCT04286412","phase":"PHASE4","title":"Nonacog Alfa Prophylaxis And Treatment Of Bleeding Episodes In Previously Treated Patients With Hemophilia B","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-02-10","conditions":"Hemophilia B","enrollment":25},{"nctId":"NCT05441553","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Efficacy of VGB-R04 in Adult Hemophilia B Patients","status":"UNKNOWN","sponsor":"Shanghai Vitalgen BioPharma Co., Ltd.","startDate":"2022-07","conditions":"Hemophilia B","enrollment":26},{"nctId":"NCT02396342","phase":"PHASE1, PHASE2","title":"Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2015-06-10","conditions":"Hemophilia B","enrollment":10},{"nctId":"NCT03358836","phase":"","title":"Joint Health Study","status":"COMPLETED","sponsor":"Bloodworks","startDate":"2017-11-15","conditions":"Hemophilia B","enrollment":8},{"nctId":"NCT02557672","phase":"PHASE4","title":"PCC vs. FFP for Post Cardiopulmonary Bypass Coagulopathy and Bleeding","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2016-08","conditions":"Bleeding, Blood Loss, Surgical, Cardiovascular Surgical Procedures","enrollment":106},{"nctId":"NCT04394286","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects","status":"TERMINATED","sponsor":"Baxalta now part of Shire","startDate":"2020-05-13","conditions":"Hemophilia B","enrollment":2},{"nctId":"NCT03417245","phase":"PHASE3","title":"A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2018-03-01","conditions":"Hemophilia A, Hemophilia B","enrollment":120},{"nctId":"NCT03417102","phase":"PHASE3","title":"A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2018-02-14","conditions":"Hemophilia A, Hemophilia B","enrollment":60},{"nctId":"NCT02234310","phase":"PHASE3","title":"Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B","status":"COMPLETED","sponsor":"Bioverativ, a Sanofi company","startDate":"2014-11-13","conditions":"Hemophilia B","enrollment":33}],"_emaApprovals":[],"_faersSignals":[{"count":834,"reaction":"HAEMORRHAGE"},{"count":251,"reaction":"HAEMARTHROSIS"},{"count":113,"reaction":"JOINT INJURY"},{"count":110,"reaction":"FALL"},{"count":101,"reaction":"DRUG INEFFECTIVE"},{"count":94,"reaction":"OFF LABEL USE"},{"count":89,"reaction":"INJURY"},{"count":88,"reaction":"ARTHRALGIA"},{"count":77,"reaction":"DISEASE COMPLICATION"},{"count":68,"reaction":"CONTUSION"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"chemblId":"CHEMBL2109205"},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":44,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Benefix","genericName":"Benefix","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:18:12.122108+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}